CA2674128A1 - Self-microemulsifying drug delivery systems - Google Patents

Self-microemulsifying drug delivery systems Download PDF

Info

Publication number
CA2674128A1
CA2674128A1 CA002674128A CA2674128A CA2674128A1 CA 2674128 A1 CA2674128 A1 CA 2674128A1 CA 002674128 A CA002674128 A CA 002674128A CA 2674128 A CA2674128 A CA 2674128A CA 2674128 A1 CA2674128 A1 CA 2674128A1
Authority
CA
Canada
Prior art keywords
emulsifier
fatty acid
self
oil
drug delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002674128A
Other languages
English (en)
French (fr)
Inventor
Igor Legen
Janez Kerc
Polona Jurkovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lek Pharmaceuticals dd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2674128A1 publication Critical patent/CA2674128A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002674128A 2006-12-27 2007-12-14 Self-microemulsifying drug delivery systems Abandoned CA2674128A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06127228A EP1961412A1 (en) 2006-12-27 2006-12-27 Self-microemulsifying drug delivery systems
EP06127228.2 2006-12-27
PCT/EP2007/063985 WO2008077823A1 (en) 2006-12-27 2007-12-14 Self-microemulsifying drug delivery systems

Publications (1)

Publication Number Publication Date
CA2674128A1 true CA2674128A1 (en) 2008-07-03

Family

ID=38002220

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002674128A Abandoned CA2674128A1 (en) 2006-12-27 2007-12-14 Self-microemulsifying drug delivery systems

Country Status (6)

Country Link
US (1) US8592490B2 (https=)
EP (2) EP1961412A1 (https=)
AT (1) ATE503460T1 (https=)
CA (1) CA2674128A1 (https=)
DE (1) DE602007013611D1 (https=)
WO (1) WO2008077823A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102342912A (zh) * 2010-08-02 2012-02-08 中国科学院上海药物研究所 坎地沙坦酯纳米乳及其制备方法
CN105640886A (zh) * 2016-03-17 2016-06-08 中国人民解放军南京军区福州总医院 一种西罗莫司自微乳制剂及其制备方法

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100278909A1 (en) * 2007-06-06 2010-11-04 Dexcel Ltd. Process for forming solid oral dosage forms of angiotensin ii receptor antagonists
DE102007052070A1 (de) 2007-10-30 2009-05-07 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Candesartancilexetil
SI2165702T1 (sl) * 2008-09-17 2012-05-31 Helm Ag Stabilni in z lahkoto raztopljeni sestavki kandesartan cileksetila pripravljeni z vlažno granulacijo
WO2010150144A2 (en) 2009-06-25 2010-12-29 Wockhardt Research Centre Low dose pharmaceutical compositions of celecoxib
CA2690490C (en) * 2010-01-19 2012-06-26 Accucaps Industries Limited Pharmaceutical formulations of loratadine for encapsulation and combinations thereof
BR112013023847B1 (pt) 2011-03-18 2021-02-23 Alkermes Pharma Ireland Limited composições farmacêuticas compreendendo ésteres de sorbitano e uso das mesmas
EP2540281A1 (en) 2011-06-30 2013-01-02 LEK Pharmaceuticals d.d. Solid self-microemulsifying systems
ES2403544B2 (es) 2011-11-11 2013-12-13 Universidade De Santiago De Compostela Sistemas nanoparticulares elaborados a base de ésteres de sorbitán.
CA2867121C (en) 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
AU2013235523B9 (en) * 2012-03-19 2018-01-04 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
AU2013235526B2 (en) 2012-03-19 2017-11-30 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
FR2991879B1 (fr) * 2012-06-14 2014-11-21 Ethypharm Sa Formulation pharmaceutique orale de molecules bcs de classe iii
JP6654042B2 (ja) 2012-09-19 2020-02-26 アルカームス ファーマ アイルランド リミテッド 貯蔵安定性が改善された医薬組成物
ES2821528T3 (es) 2012-11-14 2021-04-26 Grace W R & Co Composiciones que contienen un material biológicamente activo y un óxido inorgánico no ordenado
WO2015123272A1 (en) 2014-02-11 2015-08-20 Dr. Reddy's Laboratories Ltd. Parenteral compositions of celecoxib
CN106132415A (zh) 2014-03-20 2016-11-16 奥克梅斯制药爱尔兰有限公司 具有增加的注射速度的阿立哌唑制剂
CN104324020B (zh) * 2014-11-06 2016-09-21 江苏隆力奇生物科技股份有限公司 一种含有虾青素与白藜芦醇的自微乳颗粒制备方法
AU2016267685A1 (en) 2015-05-28 2017-12-07 Dr. Reddy's Laboratories Ltd. Oral composition of celecoxib for treatment of pain
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
EP3761983A1 (en) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
EP3915543A1 (en) 2020-05-28 2021-12-01 Evonik Operations GmbH Solid self-nanoemulsifying drug delivery system (s-snedds)
CA3144079A1 (en) 2020-12-28 2022-06-28 Biodelivery Sciences International, Inc. Methods of treating pain
US20240100165A1 (en) 2021-03-04 2024-03-28 Evonik Operations Gmbh Solid snedds based on a specific mixture of acrylic polymers
CN113750043A (zh) * 2021-09-18 2021-12-07 山东省药学科学院 一种塞来昔布自乳化口服液及其制备方法
WO2023088830A1 (en) 2021-11-18 2023-05-25 Evonik Operations Gmbh Solid snedds based on salts of methacrylic copolymers
EP4529919A1 (en) 2023-09-29 2025-04-02 Evonik Operations GmbH Solid self-nanoemulsifying drug delivery system having biosynthetic cellulose as adsorbent
WO2025177181A1 (en) * 2024-02-19 2025-08-28 Nanoprime Labs Corp Self-assembling microemulsions carrying nutraceuticals and methods for use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688761A (en) * 1991-04-19 1997-11-18 Lds Technologies, Inc. Convertible microemulsion formulations
ZA925581B (en) * 1991-07-26 1993-05-14 Smithkline Beecham Corp Pharmaceutical microemulsions.
WO1994008610A1 (en) * 1992-10-16 1994-04-28 Smithkline Beecham Corporation Pharmaceutical emulsion compositions
WO1994008605A1 (en) * 1992-10-16 1994-04-28 Smithkline Beecham Corporation Therapeutic microemulsions
AU692506B2 (en) * 1993-11-17 1998-06-11 Ibah, Inc. Transparent liquid for encapsulated drug delivery
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
GB9608719D0 (en) * 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
WO1999029316A1 (en) * 1997-12-10 1999-06-17 Severson, Mary, L. Pharmaceutical compositions containing an omega-3 fatty acid oil
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
WO2003000295A2 (en) * 2001-06-21 2003-01-03 Pfizer Products Inc. Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
EP1460992B1 (en) * 2001-12-03 2009-03-11 Dor Biopharma, Inc. Stabilized reverse micelle compositions and uses thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102342912A (zh) * 2010-08-02 2012-02-08 中国科学院上海药物研究所 坎地沙坦酯纳米乳及其制备方法
CN105640886A (zh) * 2016-03-17 2016-06-08 中国人民解放军南京军区福州总医院 一种西罗莫司自微乳制剂及其制备方法

Also Published As

Publication number Publication date
US20100331356A1 (en) 2010-12-30
EP2101729A1 (en) 2009-09-23
DE602007013611D1 (https=) 2011-05-12
ATE503460T1 (de) 2011-04-15
US8592490B2 (en) 2013-11-26
EP1961412A1 (en) 2008-08-27
WO2008077823A1 (en) 2008-07-03
EP2101729B1 (en) 2011-03-30

Similar Documents

Publication Publication Date Title
US8592490B2 (en) Self-microemulsifying drug delivery systems
CN113274355B (zh) 利福昔明固体分散体
EP3104844B1 (en) Complexes of sirolimus and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
JP2001523705A (ja) 液晶構造体を利用する薬剤送達システム
US20130172375A1 (en) Pharmaceutical composition
ES2727594T3 (es) Gránulos de liberación sostenida que contienen tacrolimus como principio activo
US12156869B2 (en) Losartan liquid formulations and methods of use
JP5661630B2 (ja) 弱イオン性化合物の剤形
KR20160128449A (ko) 칼슘 길항약／안지오텐신 ｉｉ 수용체 길항약 함유 의약 제제
US20150342882A1 (en) Methods of treatment using cadotril compositions
CZ306618B6 (cs) Kompozice obsahující sloučeniny modafinylu
KR101441450B1 (ko) 생체 이용률이 향상된 에프로살탄 고체 분산체, 이의 제조방법 및 용도
ES2663721T3 (es) Formulaciones de olmesartán
CN109260207A (zh) 嘧啶二酮衍生物化合物的制剂
US20100119607A1 (en) Bioenhanced compositions
KR102406616B1 (ko) 안지오텐신 수용체 길항제를 포함하는 약제학적 조성물 및 이의 제조방법
KR102381839B1 (ko) R-치옥트산 또는 이의 약학적으로 허용되는 염 및 유화제를 포함하는 약학조성물
WO2025109634A1 (en) Stable pharmaceutical composition of cabozantinib
EP1720523A2 (en) Cyclosporin formulations
KR20060075378A (ko) 펠로디핀 서방성 제제

Legal Events

Date Code Title Description
EEER Examination request
EEER Examination request

Effective date: 20121205

FZDE Discontinued

Effective date: 20141216